Akili Inc Ordinary Shares AKLI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AKLI is a good fit for your portfolio.
News
-
Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results
-
Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
-
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan
-
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
-
Akili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance Updates
Trading Information
- Previous Close Price
- $0.41
- Day Range
- $0.41–0.43
- 52-Week Range
- $0.19–1.67
- Bid/Ask
- $0.42 / $0.43
- Market Cap
- $33.40 Mil
- Volume/Avg
- 248,958 / 3.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.92
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Akili Inc is a digital medicine company pioneering the development of cognitive treatments through game-changing technologies.
- Sector
- Healthcare
- Industry
- Health Information Services
- Stock Style Box
- Small Growth
- Total Number of Employees
- 68
- Website
- https://www.akiliinteractive.com
Comparables
Valuation
|
Metric
|
AKLI
|
SPOK
|
ZUUS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 19.21 | — |
Price/Book Value | 0.54 | 1.84 | — |
Price/Sales | 18.92 | 2.11 | — |
Price/Cash Flow | — | 9.31 | — |
Price/Earnings
AKLI
SPOK
ZUUS
Financial Strength
|
Metric
|
AKLI
|
SPOK
|
ZUUS
|
|---|---|---|---|
Quick Ratio | 5.82 | 1.13 | 0.02 |
Current Ratio | 6.02 | 1.33 | 0.05 |
Interest Coverage | −24.21 | — | −5.16 |
Quick Ratio
AKLI
SPOK
ZUUS
Profitability
|
Metric
|
AKLI
|
SPOK
|
ZUUS
|
|---|---|---|---|
Return on Assets (Normalized) | −45.96% | 9.32% | −85.22% |
Return on Equity (Normalized) | −61.56% | 12.84% | — |
Return on Invested Capital (Normalized) | −48.51% | 11.47% | — |
Return on Assets
AKLI
SPOK
ZUUS
Health Information Services Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
GEHC
| GE HealthCare Technologies Inc Common Stock | — | Fxsvyr | $37.0 Bil | |
VEEV
| Veeva Systems Inc Class A | Mmxdpdqzhl | Rgd | $32.6 Bil | |
SOLV
| Solventum Corp | — | Jpgwv | $11.5 Bil | |
PMCUF
| Pro Medicus Ltd | — | Bmksym | $8.0 Bil | |
MTHRY
| M3 Inc ADR | — | Zxynxn | $7.5 Bil | |
MTHRF
| M3 Inc | — | Ngtvkl | $7.4 Bil | |
HQY
| HealthEquity Inc | — | Qdmmyp | $6.7 Bil | |
RCM
| R1 RCM Inc | — | Lrbt | $5.4 Bil | |
DOCS
| Doximity Inc Class A | — | Pxxbzlw | $4.5 Bil | |
EVH
| Evolent Health Inc Class A | — | Nfxtrr | $3.2 Bil |